| 2026 |
| 05/22 | 73 | 75 | 73 | 75 | +2.74% | 199,400 | 40億7494万 | -6.25% |
| 05/21 | 72 | 74 | 72 | 73 | +1.39% | 309,900 | 39億6628万 | -9.88% |
| 05/20 | (IR情報)16:45 資本金及び資本準備金の額の減少並びに剰余金の処分に関するお知らせ |
| 05/20 | (IR情報)16:45 取締役(監査等委員である取締役を除く)及び取締役(監査等委員である取締役)の報酬限度額に関するお知らせ |
| 05/20 | (IR情報)16:45 定款一部変更に関するお知らせ |
| 05/20 | (IR情報)16:45 会計監査人の異動に関するお知らせ |
| 05/20 | 75 | 75 | 72 | 72 | -5.26% | 431,800 | 39億1195万 | -11.11% |
| 05/20 | (空売り報告)Nomura International plc 967,100株(1.75%)+0.15% |
| 05/19 | 75 | 77 | 74 | 76 | +4.11% | 530,900 | 41億2928万 | -7.32% |
| 05/19 | (空売り報告)Nomura International plc 885,700株(1.6%)-0.16% |
| 05/19 | (空売り報告)MERRILL LYNCH INTERNATIONAL 296,430株(0.54%)-0.01% |
| 05/19 | (空売り報告)Barclays Capital Securities Ltd 1,475,551株(2.67%)-0.23% |
| 05/18 | (IR情報)18:00 2026年3月期決算説明会資料 |
| 05/18 | 76 | 76 | 73 | 73 | -2.67% | 632,500 | 39億6628万 | -10.98% |
| 05/18 | (空売り報告)Nomura International plc 971,700株(1.76%)+0.16% |
| 05/18 | (空売り報告)Barclays Capital Securities Ltd 1,597,651株(2.9%)-0.31% |
| 05/15 | 76 | 78 | 75 | 75 | -1.32% | 430,800 | 40億7494万 | -9.64% |
| 05/15 | (空売り報告)Barclays Capital Securities Ltd 1,772,651株(3.21%)-0.18% |
| 05/14 | (IR情報)15:30 営業外収益(助成金収入・為替差益)及び特別損失(固定資産の減損損失)の計上に関するお知らせ |
| 05/14 | (IR情報)15:30 2026年3月期決算短信〔日本基準〕(非連結) |
| 05/14 | (IR情報)15:30 Fusion Conference 2026「Fibroblast Growth Factor Signaling in Development, Health & Disease Conference」での登壇資料 |
| 05/14 | 78 | 79 | 76 | 76 | -2.56% | 431,500 | 41億2928万 | -9.52% |
| 05/14 | (空売り報告)Barclays Capital Securities Ltd 1,868,351株(3.39%)-0.04% |
| 05/13 | (5%ルール)エボファンド(Evo Fund)(30.35%)エボリューション・キャピタル・マネジメント・エル…(0%) |
| 05/13 | 77 | 79 | 76 | 78 | +1.3% | 404,900 | 42億3794万 | -7.14% |
| 05/13 | (空売り報告)Barclays Capital Securities Ltd 1,892,451株(3.43%)-0.14% |
| 05/12 | 80 | 80 | 77 | 77 | -3.75% | 725,800 | 41億8361万 | -9.41% |
| 05/12 | (空売り報告)Nomura International plc 886,000株(1.6%)+0.13% |
| 05/12 | (空売り報告)MERRILL LYNCH INTERNATIONAL 302,430株(0.55%)-0.07% |
| 05/12 | (空売り報告)Barclays Capital Securities Ltd 1,967,451株(3.57%)+0.49% |
| 05/11 | 81 | 81 | 80 | 80 | -1.23% | 183,500 | 43億4661万 | -5.88% |
| 05/11 | (空売り報告)Nomura International plc 810,600株(1.47%)+0.13% |
| 05/08 | 81 | 82 | 80 | 81 | 0% | 306,400 | 44億94万 | -5.81% |
| 05/08 | (空売り報告)Barclays Capital Securities Ltd 1,700,951株(3.08%)-0.03% |
| 05/07 | 80 | 82 | 79 | 81 | +2.53% | 619,700 | 44億94万 | -5.81% |
| 05/07 | (空売り報告)Nomura International plc 739,800株(1.34%)-0.18% |
| 05/07 | (空売り報告)MERRILL LYNCH INTERNATIONAL 339,730株(0.62%)+0.02% |
| 05/07 | (空売り報告)Barclays Capital Securities Ltd 1,713,951株(3.11%)-0.18% |
| 05/01 | (IR情報)15:30 第三者割当により発行された第19回新株予約権(行使価額修正条項付)の月間行使状況に関するお知らせ |
| 05/01 | 79 | 81 | 79 | 79 | 0% | 342,100 | 42億9227万 | -8.14% |
| 05/01 | (空売り報告)Arrowstreet Capital, Limited Partnership 1,468,600株(2.66%)+1.2% |
| 05/01 | (空売り報告)Barclays Capital Securities Ltd 1,790,551株(3.29%)-0.04% |
| 04/30 | 79 | 81 | 79 | 79 | 0% | 497,000 | 42億9227万 | -9.2% |
| 04/30 | (空売り報告)Nomura International plc 827,500株(1.52%)+0.06% |
| 04/30 | (空売り報告)Barclays Capital Securities Ltd 1,812,551株(3.33%)-0.22% |
| 04/28 | 80 | 80 | 79 | 79 | -1.25% | 347,700 | 42億9227万 | -10.23% |
| 04/28 | (空売り報告)Barclays Capital Securities Ltd 1,933,651株(3.55%)-0.14% |
| 04/27 | 82 | 82 | 80 | 80 | -2.44% | 471,800 | 43億4661万 | -9.09% |
| 04/27 | (空売り報告)Nomura International plc 796,800株(1.46%)+0.14% |
| 04/27 | (空売り報告)Barclays Capital Securities Ltd 2,006,951株(3.69%)+0.26% |
| 04/24 | 83 | 84 | 82 | 82 | -1.2% | 305,400 | 44億5527万 | -7.87% |
| 04/24 | (空売り報告)MERRILL LYNCH INTERNATIONAL 330,930株(0.6%)+0.03% |
| 04/24 | (空売り報告)Barclays Capital Securities Ltd 1,868,751株(3.43%)-0.14% |
| 04/23 | (IR情報)15:30 Fusion Conference 2026における軟骨無形成症治療薬(umedaptanib pegol)第II相臨床試験の結果に関する講演のお知らせ |
| 04/23 | 84 | 85 | 82 | 83 | -2.35% | 547,400 | 45億960万 | -7.78% |
| 04/23 | (空売り報告)野村證券 279,499株(0.51%)+0.01% |
| 04/23 | (空売り報告)Barclays Capital Securities Ltd 1,943,651株(3.57%)+0.1% |
| 04/22 | 86 | 87 | 84 | 85 | -1.16% | 733,600 | 46億1827万 | -5.56% |
| 04/22 | (空売り報告)Barclays Capital Securities Ltd 1,886,351株(3.47%)+0.28% |
| 04/21 | (5%ルール)エボファンド(Evo Fund)(30.79%)エボリューション・キャピタル・マネジメント・エル…(0%) |
| 04/21 | 87 | 88 | 86 | 86 | -1.15% | 305,000 | 46億7260万 | -4.44% |
| 04/21 | (空売り報告)MERRILL LYNCH INTERNATIONAL 310,630株(0.57%)+0.03% |
| 04/20 | 86 | 88 | 86 | 87 | +1.16% | 423,400 | 47億2693万 | -4.4% |
| 04/20 | (空売り報告)Nomura International plc 719,400株(1.32%)-0.1% |
| 04/20 | (空売り報告)MERRILL LYNCH INTERNATIONAL 298,730株(0.54%)再IN |
| 04/17 | 88 | 89 | 86 | 86 | 0% | 753,000 | 46億7260万 | -5.49% |
| 04/17 | (空売り報告)Nomura International plc 776,600株(1.42%)+0.07% |
| 04/17 | (空売り報告)Barclays Capital Securities Ltd 1,734,451株(3.19%)+0.28% |
| 04/16 | (IR情報)15:30 SK Plasmaとの共同研究契約締結に関するお知らせ |
| 04/16 | 86 | 87 | 86 | 86 | 0% | 126,300 | 46億7260万 | -6.52% |
| 04/16 | (空売り報告)Nomura International plc 736,600株(1.35%)-0.05% |
| 04/15 | 87 | 87 | 85 | 86 | 0% | 1,042,500 | 46億7260万 | -7.53% |
| 04/15 | (空売り報告)Nomura International plc 762,300株(1.4%)+0.04% |
| 04/15 | (空売り報告)Barclays Capital Securities Ltd 1,585,251株(2.91%)-0.12% |
| 04/14 | (IR情報)15:30 監査等委員会設置会社への移行に伴う役員人事に関するお知らせ |
| 04/14 | 87 | 88 | 86 | 86 | -1.15% | 451,600 | 46億7260万 | -7.53% |
| 04/14 | (空売り報告)MERRILL LYNCH INTERNATIONAL 141,230株(0.25%)-0.27%義務消失 |
| 04/14 | (空売り報告)Barclays Capital Securities Ltd 1,650,951株(3.03%)-0.21% |
| 04/13 | 86 | 87 | 86 | 87 | +1.16% | 127,500 | 47億2693万 | -7.45% |
| 04/13 | (空売り報告)MERRILL LYNCH INTERNATIONAL 287,430株(0.52%)+0.01% |
| 04/10 | (IR情報)15:30 情報開示の透明性向上に向けたQ&A運用方法変更に関するお知らせ |
| 04/10 | 89 | 89 | 86 | 86 | -2.27% | 755,400 | 46億7260万 | -8.51% |
| 04/10 | (空売り報告)Nomura International plc 742,400株(1.36%)+0.11% |
| 04/10 | (空売り報告)MERRILL LYNCH INTERNATIONAL 279,630株(0.51%)再IN |
| 04/10 | (空売り報告)Barclays Capital Securities Ltd 1,761,551株(3.24%)+0.64% |
| 04/09 | 91 | 92 | 88 | 88 | -4.35% | 1,427,900 | 47億8127万 | -6.38% |
| 04/09 | (空売り報告)Nomura International plc 681,900株(1.25%)+0.09% |
| 04/09 | (空売り報告)Barclays Capital Securities Ltd 1,413,351株(2.6%)+0.13% |
| 04/08 | 90 | 93 | 89 | 92 | +2.22% | 875,200 | 49億9860万 | -2.13% |
| 04/08 | (空売り報告)Barclays Capital Securities Ltd 1,344,751株(2.47%)-0.22% |
| 04/07 | 91 | 92 | 89 | 90 | -1.1% | 619,000 | 48億8993万 | -4.26% |
| 04/07 | (空売り報告)Barclays Capital Securities Ltd 1,465,951株(2.69%)-0.2% |
| 04/06 | (5%ルール)エボファンド(Evo Fund)(30.83%)エボリューション・キャピタル・マネジメント・エル…(0%) |
| 04/06 | 90 | 91 | 89 | 91 | +1.11% | 481,800 | 49億4427万 | -3.19% |
| 04/06 | (空売り報告)Barclays Capital Securities Ltd 1,574,051株(2.89%)-0.11% |
| 04/03 | 90 | 92 | 90 | 90 | 0% | 563,300 | 48億8993万 | -4.26% |
| 04/03 | (空売り報告)Barclays Capital Securities Ltd 1,633,651株(3%)-0.27% |
| 04/02 | (IR情報)12:00 軟骨無形成症治療薬(umedaptanib pegol)の国内第III相臨床試験開始許諾に関するお知らせ |
| 04/02 | 91 | 95 | 88 | 90 | -1.1% | 1,790,700 | 48億8993万 | -4.26% |
| 04/02 | (空売り報告)Nomura International plc 633,700株(1.16%)-0.22% |
| 04/02 | (空売り報告)Barclays Capital Securities Ltd 1,777,351株(3.27%)+0.32% |
| 04/01 | 88 | 91 | 88 | 91 | +3.41% | 1,044,200 | 49億4427万 | -3.19% |
| 04/01 | (空売り報告)Nomura International plc 752,300株(1.38%)-0.28% |
| 03/31 | (IR情報)15:30 三菱商事ライフサイエンス株式会社との共同研究開発契約終了のお知らせ |
| 03/31 | 89 | 91 | 87 | 88 | -2.22% | 1,094,100 | 47億8127万 | -5.38% |
| 03/31 | (空売り報告)Nomura International plc 905,000株(1.66%)-0.1% |
| 03/31 | (空売り報告)Barclays Capital Securities Ltd 1,605,851株(2.95%)+0.06% |
| 03/30 | 90 | 91 | 88 | 90 | -4.26% | 1,513,900 | 48億8993万 | -3.23% |
| 03/30 | (空売り報告)Nomura International plc 957,700株(1.76%)+0.47% |
| 03/27 | 98 | 98 | 93 | 94 | -1.05% | 3,213,100 | 51億726万 | +1.08% |
| 03/27 | (空売り報告)Nomura International plc 704,600株(1.29%)+0.68% |
| 03/27 | (空売り報告)Citigroup Global Markets Limited 263,900株(0.48%)-0.02%義務消失 |
| 03/27 | (空売り報告)Barclays Capital Securities Ltd 1,572,451株(2.89%)+0.9% |
| 03/26 | (IR情報)15:30 日産化学株式会社との共同研究契約締結のお知らせ |
| 03/26 | 98 | 99 | 93 | 95 | -3.06% | 1,521,500 | 51億6160万 | +2.15% |
| 03/26 | (空売り報告)Nomura International plc 334,000株(0.61%)+0.08% |
| 03/26 | (空売り報告)Barclays Capital Securities Ltd 1,085,585株(1.99%)-0.14% |
| 03/25 | 93 | 100 | 93 | 98 | +5.38% | 1,598,300 | 53億2459万 | +6.52% |
| 03/25 | (空売り報告)Nomura International plc 293,000株(0.53%)-0.51% |
| 03/25 | (空売り報告)モルガン・スタンレーMUFG証券 267,900株(0.49%)-0.02%義務消失 |
| 03/25 | (空売り報告)Barclays Capital Securities Ltd 1,158,885株(2.13%)-0.45% |
| 03/24 | (IR情報)15:30 アナリストレポート公開のお知らせ |
| 03/24 | 93 | 94 | 91 | 93 | +2.2% | 1,711,900 | 50億5293万 | +2.2% |
| 03/24 | (空売り報告)JPM Securities Japan Co Ltd. 259,400株(0.47%)-0.1%義務消失 |
| 03/24 | (空売り報告)Nomura International plc 568,500株(1.04%)-0.39% |
| 03/23 | 92 | 94 | 90 | 91 | -8.08% | 3,053,800 | 49億4427万 | 0% |
| 03/23 | (空売り報告)JPM Securities Japan Co Ltd. 312,000株(0.57%)-0.09% |
| 03/23 | (空売り報告)Nomura International plc 781,400株(1.43%)+0.07% |
| 03/19 | 105 | 116 | 96 | 99 | +4.21% | 20,657,400 | 53億7893万 | +8.79% |
| 03/19 | (空売り報告)JPM Securities Japan Co Ltd. 360,700株(0.66%)+0.13% |
| 03/19 | (空売り報告)Nomura International plc 740,000株(1.36%)+0.34% |
| 03/19 | (空売り報告)Barclays Capital Securities Ltd 1,404,885株(2.58%)+1.92% |
| 03/18 | (IR情報)15:30 軟骨無形成症治療薬(umedaptanib pegol)の国内第III相臨床試験治験申請のお知らせ |
| 03/18 | (IR情報)15:30 RBM-011(抗Interleukin-21アプタマー)に関する物質特許の米国における特許査定のお知らせ |
| 03/18 | 96 | 98 | 95 | 95 | -1.04% | 1,021,600 | 51億6160万 | +5.56% |
| 03/18 | (空売り報告)Nomura International plc 556,600株(1.02%)-0.3% |
| 03/17 | (IR情報)15:30 第三者割当による第18回新株予約権乃至第20回新株予約権(行使価額修正条項付)に係る資金使途変更に関するお知らせ |
| 03/17 | (IR情報)15:30 第三者割当による第15回新株予約権(行使価額修正条項付)及び第17回新株予約権(行使価額修正条項付)に係る資金使途の支出予定時期の変更に関するお知らせ |
| 03/17 | 100 | 101 | 96 | 96 | -3.03% | 1,652,000 | 52億1593万 | +6.67% |
| 03/17 | (空売り報告)Nomura International plc 717,200株(1.32%)+0.31% |
| 03/16 | (IR情報)15:30 Keystone Symposia「Nucleic Acia Therapeutics and Targeted Delivery」での登壇資料 |
| 03/16 | (IR情報)15:30 新規PEG代替技術に関する物質特許の台湾における特許査定のお知らせ |
| 03/16 | 96 | 101 | 94 | 99 | +4.21% | 2,058,600 | 53億7893万 | +11.24% |
| 03/16 | (空売り報告)Nomura International plc 553,300株(1.01%)+0.11% |
| 03/16 | (空売り報告)Citigroup Global Markets Limited 274,400株(0.5%)再IN |
| 03/16 | (空売り報告)Barclays Capital Securities Ltd 359,045株(0.66%)-0.1% |
| 03/13 | 99 | 99 | 94 | 95 | -5.94% | 2,697,000 | 51億6160万 | +6.74% |
| 03/13 | (空売り報告)Nomura International plc 492,900株(0.9%)-0.14% |
| 03/13 | (空売り報告)Barclays Capital Securities Ltd 414,645株(0.76%)-0.4% |
| 03/12 | 105 | 108 | 100 | 101 | -6.48% | 4,528,900 | 54億8759万 | +14.77% |
| 03/12 | (空売り報告)Nomura International plc 565,400株(1.04%)-0.58% |
| 03/12 | (空売り報告)モルガン・スタンレーMUFG証券 279,200株(0.51%)-0.18% |
| 03/12 | (空売り報告)MERRILL LYNCH INTERNATIONAL 219,930株(0.4%)-0.1%義務消失 |
| 03/12 | (空売り報告)Citigroup Global Markets Limited 268,300株(0.49%)-0.01%義務消失 |
| 03/12 | (空売り報告)Barclays Capital Securities Ltd 632,945株(1.16%)-0.47% |
| 03/11 | 117 | 120 | 106 | 108 | +8% | 20,579,100 | 58億6792万 | +24.14% |
| 03/11 | (空売り報告)JPM Securities Japan Co Ltd. 291,200株(0.53%)再IN |
| 03/11 | (空売り報告)Nomura International plc 884,400株(1.62%)+0.24% |
| 03/11 | (空売り報告)MERRILL LYNCH INTERNATIONAL 274,130株(0.5%)再IN |
| 03/11 | (空売り報告)Citigroup Global Markets Limited 274,400株(0.5%)新規 |
| 03/11 | (空売り報告)Barclays Capital Securities Ltd 886,201株(1.63%)再IN |
| 03/10 | (IR情報)15:30 軟骨無形成症治療薬(umedaptanib pegol)国内第II相臨床試験主要評価項目に関する総括報告のお知らせ |
| 03/10 | 95 | 101 | 92 | 100 | +5.26% | 3,807,600 | 54億3326万 | +16.28% |
| 03/10 | (空売り報告)Nomura International plc 755,100株(1.38%)-0.58% |
| 03/09 | 93 | 95 | 88 | 95 | -2.06% | 2,368,300 | 51億6160万 | +10.47% |
| 03/09 | (空売り報告)Nomura International plc 1,065,500株(1.96%)+0.17% |
| 03/06 | 91 | 100 | 90 | 97 | +6.59% | 3,719,400 | 52億7026万 | +14.12% |
| 03/06 | (空売り報告)Nomura International plc 972,800株(1.79%)-0.01% |
| 03/05 | 90 | 94 | 88 | 91 | +5.81% | 2,161,600 | 49億4427万 | +7.06% |
| 03/05 | (空売り報告)Nomura International plc 982,544株(1.8%)-0.3% |
| 03/05 | (空売り報告)モルガン・スタンレーMUFG証券 379,700株(0.69%)-0.18% |
| 03/04 | 92 | 94 | 86 | 86 | -13.13% | 8,128,300 | 46億7260万 | +1.18% |
| 03/04 | (空売り報告)Nomura International plc 1,144,900株(2.1%)+0.24% |
| 03/04 | (空売り報告)Barclays Capital Securities Ltd 0株(0%)-1.17%義務消失 |
| 03/03 | 88 | 116 | 86 | 99 | +15.12% | 48,506,700 | 53億7893万 | +16.47% |
| 03/03 | (空売り報告)Nomura International plc 1,015,300株(1.86%)+1.04% |
| 03/03 | (空売り報告)モルガン・スタンレーMUFG証券 473,800株(0.87%)再IN |
| 03/03 | (空売り報告)Barclays Capital Securities Ltd 637,100株(1.17%)再IN |
| 03/02 | 86 | 86 | 84 | 86 | 0% | 413,000 | 46億7260万 | +2.38% |
| 02/27 | 84 | 86 | 84 | 86 | +1.18% | 366,800 | 46億7260万 | +1.18% |
| 02/27 | (空売り報告)Nomura International plc 448,800株(0.82%)-0.13% |
| 02/26 | 83 | 85 | 83 | 85 | +1.19% | 314,900 | 46億1827万 | 0% |
| 02/26 | (空売り報告)Nomura International plc 518,500株(0.95%)-0.19% |
| 02/25 | 84 | 84 | 82 | 84 | 0% | 219,400 | 45億6394万 | -1.18% |
| 02/24 | 84 | 85 | 82 | 84 | 0% | 367,200 | 45億6394万 | -1.18% |
| 02/20 | 85 | 86 | 83 | 84 | 0% | 365,600 | 45億6394万 | -1.18% |
| 02/20 | (空売り報告)Nomura International plc 620,700株(1.14%)+0.06% |
| 02/19 | 85 | 86 | 83 | 84 | +1.2% | 518,400 | 45億6394万 | -1.18% |
| 02/19 | (空売り報告)モルガン・スタンレーMUFG証券 241,300株(0.44%)-0.15%義務消失 |
| 02/18 | 83 | 84 | 83 | 83 | +1.22% | 246,100 | 45億960万 | -2.35% |
| 02/17 | 82 | 83 | 81 | 82 | 0% | 255,100 | 44億5527万 | -3.53% |
| 02/16 | (IR情報)15:30 軟骨無形成症治療薬umedaptanib pegolに対する令和7年度希少疾病用医薬品等試験研究助成金の交付額増額のお知らせ |
| 02/16 | (IR情報)15:30 代表取締役社長の中村義一がKeystone Symposia「Nucleic Acid Therapeutics and Targeted Delivery」に登壇します |
| 02/16 | 82 | 83 | 81 | 82 | 0% | 518,500 | 44億5527万 | -4.65% |
| 02/16 | (空売り報告)Nomura International plc 590,800株(1.08%)-0.05% |
| 02/13 | 86 | 86 | 81 | 82 | -4.65% | 651,600 | 44億5527万 | -4.65% |
| 02/13 | (空売り報告)Nomura International plc 615,300株(1.13%)+0.13% |
| 02/13 | (空売り報告)モルガン・スタンレーMUFG証券 323,600株(0.59%)-0.09% |
| 02/12 | (IR情報)15:30 2026年3月期第3四半期決算短信〔日本基準〕(非連結) |
| 02/12 | (IR情報)15:30 営業外収益(為替差益)の計上に関するお知らせ |
| 02/12 | 86 | 87 | 86 | 86 | 0% | 317,300 | 46億7260万 | 0% |
| 02/10 | 83 | 87 | 83 | 86 | +3.61% | 510,000 | 46億7260万 | +1.18% |
| 02/10 | (空売り報告)Nomura International plc 545,100株(1%)-0.16% |
| 02/09 | 83 | 84 | 82 | 83 | +1.22% | 104,300 | 45億960万 | -2.35% |
| 02/06 | 83 | 83 | 82 | 82 | -1.2% | 316,900 | 44億5527万 | -3.53% |
| 02/05 | 83 | 84 | 82 | 83 | 0% | 165,800 | 45億960万 | -2.35% |
| 02/04 | 83 | 83 | 82 | 83 | 0% | 198,100 | 45億960万 | -1.19% |
| 02/03 | 83 | 84 | 83 | 83 | 0% | 213,500 | 45億960万 | -1.19% |
| 02/02 | 84 | 86 | 83 | 83 | -1.19% | 435,700 | 45億960万 | -1.19% |
| 01/30 | 84 | 85 | 83 | 84 | 0% | 306,900 | 45億6394万 | +1.2% |
| 01/30 | (空売り報告)Barclays Capital Securities Ltd 247,744株(0.45%)-0.05%義務消失 |
| 01/29 | 86 | 86 | 84 | 84 | -2.33% | 424,700 | 45億6394万 | +1.2% |
| 01/29 | (空売り報告)Nomura International plc 630,500株(1.16%)-0.04% |
| 01/29 | (空売り報告)Barclays Capital Securities Ltd 272,244株(0.5%)再IN |
| 01/28 | (IR情報)15:30 個人投資家向け会社説明会「バイオIR Day」参加のお知らせ |
| 01/28 | 87 | 88 | 85 | 86 | -1.15% | 620,500 | 46億7260万 | +3.61% |
| 01/28 | (空売り報告)Nomura International plc 653,700株(1.2%)-0.21% |
| 01/28 | (空売り報告)Barclays Capital Securities Ltd 256,544株(0.47%)-0.17%義務消失 |
| 01/27 | 88 | 88 | 86 | 87 | 0% | 237,000 | 47億2693万 | +6.1% |
| 01/26 | (IR情報)15:30 第17回次世代モダリティセミナー講演のお知らせ |
| 01/26 | 89 | 89 | 87 | 87 | -3.33% | 539,800 | 47億2693万 | +6.1% |
| 01/26 | (空売り報告)Nomura International plc 770,800株(1.41%)+0.1% |
| 01/26 | (空売り報告)Barclays Capital Securities Ltd 351,144株(0.64%)+0.06% |
| 01/23 | 90 | 90 | 88 | 90 | 0% | 391,700 | 48億8993万 | +11.11% |
| 01/23 | (空売り報告)Nomura International plc 712,300株(1.31%)+0.08% |
| 01/22 | 90 | 90 | 88 | 90 | +1.12% | 349,300 | 48億8993万 | +11.11% |
| 01/21 | 89 | 91 | 88 | 89 | -2.2% | 1,020,000 | 47億210万 | +11.25% |
| 01/21 | (空売り報告)Nomura International plc 671,400株(1.23%)-0.14% |
| 01/20 | 95 | 95 | 90 | 91 | -2.15% | 1,334,300 | 48億777万 | +13.75% |
| 01/20 | (空売り報告)Nomura International plc 746,900株(1.37%)+0.37% |
| 01/20 | (空売り報告)モルガン・スタンレーMUFG証券 363,500株(0.68%)-0.02% |
| 01/20 | (空売り報告)Barclays Capital Securities Ltd 319,344株(0.58%)再IN |
| 01/19 | 93 | 96 | 90 | 93 | +5.68% | 2,491,300 | 49億1343万 | +17.72% |
| 01/19 | (空売り報告)UBS AG 220,500株(0.4%)-0.14%義務消失 |
| 01/19 | (空売り報告)Nomura International plc 548,400株(1%)-0.16% |
| 01/19 | (空売り報告)モルガン・スタンレーMUFG証券 370,100株(0.7%)+0.04% |
| 01/16 | (IR情報)15:30 (訂正)2026年3月期第2四半期決算説明会資料の一部訂正のお知らせ |
| 01/16 | (IR情報)14:00 AIでRNAアプタマー創薬を効率化する新技術「RaptScore」の開発と論文発表のお知らせ |
| 01/16 | 87 | 92 | 86 | 88 | +2.33% | 2,743,700 | 46億4927万 | +12.82% |
| 01/16 | (空売り報告)Nomura International plc 632,300株(1.16%)-0.36% |
| 01/16 | (空売り報告)Barclays Capital Securities Ltd 184,244株(0.33%)-0.19%義務消失 |
| 01/15 | 86 | 88 | 84 | 86 | +3.61% | 2,137,800 | 45億4360万 | +10.26% |
| 01/15 | (空売り報告)Nomura International plc 828,400株(1.52%)-0.16% |
| 01/15 | (空売り報告)モルガン・スタンレーMUFG証券 353,800株(0.66%)-0.22% |
| 01/15 | (空売り報告)Barclays Capital Securities Ltd 285,444株(0.52%)再IN |
| 01/14 | (IR情報)15:30 高活性RBM-006(抗オートタキシンアプタマー)の新規物質特許出願とマウス糖尿病網膜症モデルにおける薬効確認のお知らせ |
| 01/14 | 84 | 85 | 83 | 83 | -1.19% | 390,300 | 43億8510万 | +7.79% |
| 01/13 | 84 | 85 | 81 | 84 | 0% | 888,300 | 44億3794万 | +9.09% |
| 01/13 | (空売り報告)Nomura International plc 917,100株(1.68%)+0.09% |
| 01/13 | (空売り報告)モルガン・スタンレーMUFG証券 469,500株(0.88%)-0.05% |
| 01/09 | 86 | 86 | 83 | 84 | 0% | 796,700 | 44億3794万 | +9.09% |
| 01/09 | (空売り報告)UBS AG 297,100株(0.54%)再IN |
| 01/09 | (空売り報告)Nomura International plc 867,200株(1.59%)-0.04% |
| 01/08 | 83 | 87 | 83 | 84 | +3.7% | 2,219,600 | 44億3794万 | +9.09% |
| 01/08 | (空売り報告)Nomura International plc 886,300株(1.63%)-0.16% |
| 01/08 | (空売り報告)モルガン・スタンレーMUFG証券 492,700株(0.93%)+0.39% |
| 01/07 | 79 | 83 | 79 | 81 | +1.25% | 632,000 | 42億7944万 | +5.19% |
| 01/07 | (空売り報告)UBS AG 222,400株(0.4%)-0.19%義務消失 |
| 01/06 | 78 | 80 | 78 | 80 | +2.56% | 746,500 | 42億2661万 | +3.9% |
| 01/05 | 78 | 79 | 76 | 78 | 0% | 554,900 | 41億2094万 | +1.3% |
| 01/05 | (空売り報告)UBS AG 322,900株(0.59%)-0.1% |
| 01/05 | (空売り報告)Nomura International plc 977,444株(1.79%)-0.08% |
| 2025 |
| 12/30 | 76 | 78 | 75 | 78 | +1.3% | 526,800 | 41億2094万 | +1.3% |
| 12/29 | 75 | 77 | 74 | 77 | +2.67% | 453,700 | 40億6811万 | 0% |
| 12/29 | (空売り報告)Nomura International plc 1,018,000株(1.87%)-0.05% |
| 12/26 | 76 | 76 | 74 | 75 | -1.32% | 776,900 | 39億6244万 | -3.85% |
| 12/26 | (空売り報告)UBS AG 377,200株(0.69%)+0.13% |
| 12/26 | (空売り報告)モルガン・スタンレーMUFG証券 288,500株(0.54%)-0.07% |
| 12/25 | 74 | 76 | 73 | 76 | +2.7% | 817,600 | 40億1528万 | -2.56% |
| 12/25 | (空売り報告)UBS AG 304,900株(0.56%)-0.06% |
| 12/25 | (空売り報告)Nomura International plc 1,047,600株(1.92%)-0.16% |
| 12/24 | 74 | 75 | 74 | 74 | 0% | 307,700 | 39億961万 | -5.13% |
| 12/24 | (空売り報告)野村證券 264,199株(0.5%)再IN |
| 12/23 | 74 | 76 | 74 | 74 | 0% | 410,500 | 39億961万 | -5.13% |
| 12/23 | (空売り報告)野村證券 263,199株(0.49%)-0.08%義務消失 |
| 12/23 | (空売り報告)UBS AG 337,200株(0.62%)-0.08% |
| 12/23 | (空売り報告)Nomura International plc 1,131,100株(2.08%)-0.03% |
| 12/22 | 75 | 77 | 74 | 74 | -1.33% | 502,400 | 38億3561万 | -6.33% |
| 12/22 | (空売り報告)UBS AG 381,600株(0.7%)-0.31% |
| 12/22 | (空売り報告)Nomura International plc 1,146,700株(2.11%)-0.13% |
| 12/22 | (空売り報告)モルガン・スタンレーMUFG証券 326,500株(0.61%)+0.1% |
| 12/19 | 73 | 76 | 73 | 75 | +1.35% | 696,300 | 38億8744万 | -5.06% |
| 12/19 | (空売り報告)UBS AG 553,500株(1.01%)-0.11% |
| 12/18 | (IR情報)15:30 三菱商事ライフサイエンス株式会社との共同研究開発に伴う化粧品原料候補「抗好中球エラスターゼアプタマー」のPCT出願完了のお知らせ |
| 12/18 | (空売り報告)モルガン・スタンレーMUFG証券 266,200株(0.51%)再IN |
| 12/17 | (5%ルール)エボファンド(Evo Fund)(32.13%)エボリューション・キャピタル・マネジメント・エル…(0%) |
| 12/17 | (空売り報告)UBS AG 612,900株(1.12%)+0.29% |
| 12/17 | (空売り報告)Nomura International plc 1,217,500株(2.24%)-0.13% |
| 12/17 | (空売り報告)モルガン・スタンレーMUFG証券 230,400株(0.44%)-0.14%義務消失 |
| 12/16 | (5%ルール)エボファンド(Evo Fund)(32.4%)エボリューション・キャピタル・マネジメント・エル…(0%) |
| 12/16 | (空売り報告)UBS AG 449,800株(0.83%)+0.1% |
| 12/16 | (空売り報告)Nomura International plc 1,284,300株(2.37%)+0.4% |
| 12/16 | (空売り報告)モルガン・スタンレーMUFG証券 302,500株(0.58%)再IN |
| 12/15 | (IR情報)15:30 業績予想の修正に関するお知らせ |
| 12/15 | (IR情報)15:30 リードファーマ株式会社とのアプタマーを利用した薬剤送達技術を用いた中枢神経疾患治療薬の創出に関する共同研究契約締結のお知らせ |
| 12/15 | (IR情報)15:30 当社の従業員に対する譲渡制限付株式としての新株式発行の払込完了に関するお知らせ |
| 12/15 | (空売り報告)UBS AG 398,300株(0.73%)-0.17% |
| 12/15 | (空売り報告)Nomura International plc 1,068,300株(1.97%)+0.13% |